KPMG advisory for site selection for life sciences in Europe

Site Selection for Life Sciences Companies in Europe

Focus on supporting your ESG strategy.

Many locations across Europe may be suitable for your regional headquarters, shared service centers, manufacturing, warehousing or R&D facilities. But do they also support your ESG strategies?

In this 2024 edition of Site Selection for Life Sciences Companies in Europe, we compare European countries based on their general business environment, infrastructure, innovation, R&D, availability of skilled personnel and other critical factors. But we also look at factors relevant to the efficient implementation of a company's ESG strategy, such as the availability of green energy, wastewater treatment, gender equality, work-life balance, public transportation and corruption. The presence or absence of such factors can be important for companies planning to efficiently support their ESG strategies. EU reporting requirements such as the EU Corporate Sustainability Directive (CSRD) are also explained.

But the EU and various European countries are not only implementing new regulations related to the "European Green Deal", they have also implemented many different programs that support life sciences companies in their growth ambitions. In this report, you'll find an overview of such programs at the EU level.

André Guedel

Director, Head Business Development Tax

KPMG Switzerland


Key findings

  1. Declining importance of tax rates

    Competitive tax rates and tax incentives remain important but have diminished in importance due to the minimum tax rates proposed in BEPS 2.0.

  2. Productivity and Sustainability

    Conversely, productivity and, more importantly, sustainability factors are becoming increasingly important to executives looking to locate their life sciences-related operations in Europe.

  3. Complex reporting requirements

    The EU Corporate Sustainability Reporting Directive (CSRD) has set new standards for sustainability and corporate responsibility. These initiatives require life sciences companies to increase transparency and meet stringent environmental and social standards.

  4. EU-wide programs to support the life sciences industry

    The EU is firmly committed to maintaining its position as a leading economic bloc for the development and manufacture of life sciences products. It has put in place several programs and strategies to support the life sciences industry and has also made significant funds available to support R&D and green transition. It remains to be seen whether these initiatives will contribute to the creation of new highly skilled jobs and new groundbreaking scientific results. 

Choice of location for life sciences companies

Site Selection for life sciences companies in Europe

Site Selection for life sciences companies in Europe

Related articles

Harnessing the power of the human microbiome

What is the microbiome? What does the market look like, what are potential challenges and what are future trends?

Site Selection for Life Sciences Companies in Africa

Building life sciences manufacturing plants in Sub-Saharan Africa is being recognized as decisive factor to strengthen the local healthcare ecosystems.

Site Selection for Life Sciences Companies in Asia

Navigate the landscape of Asia’s most dynamic and diverse Life Sciences markets.

Choice of location for life sciences companies in Europe

Finding the right location to start or expand a business is not easy. You should consider these key issues (Website in German).

Haven't found what you were looking for?

Our global network of pharmaceutical medtech, biotech and data experts empower startups and large multinationals to make better business decisions.
nurse working on tablet